Jefferies Financial Group Begins Coverage on Allogene Therapeutics (ALLO)

Jefferies Financial Group initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research note issued to investors on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $31.00 target price on the stock.

Separately, Goldman Sachs Group started coverage on shares of Allogene Therapeutics in a research report on Monday. They set a buy rating and a $41.00 target price for the company.

Allogene Therapeutics stock opened at $32.68 on Monday. Allogene Therapeutics has a twelve month low of $21.67 and a twelve month high of $35.55.

In other Allogene Therapeutics news, Director Arie Belldegrun purchased 35,000 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $630,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider David D. Chang purchased 40,000 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $720,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 750,000 shares of company stock worth $13,500,000 over the last 90 days.

Featured Article: Should You Consider an Index Fund?

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply